Cutter's product, Koate HT, had been available since November 1984. Read more about Cutter's product, Koate HT, had been available since November 1984.
Christopher Bishop wanted to prepare a "defence" document designed to restore confidence in Armour's heat treatment process and stop further deterioration in sales. Read more about Christopher Bishop wanted to prepare a "defence" document designed to restore confidence in Armour's heat treatment process and stop further deterioration in sales.
A memo from Dr Harris to Mr Christie outlined that he was now obliged to report Dr Whitmore's seroconverted patient to Dr Rotblatt as Dr Whitmore had confirmed that the patient remained HTLV-3 positive following receipt of heat-treated Factorate. Read more about A memo from Dr Harris to Mr Christie outlined that he was now obliged to report Dr Whitmore's seroconverted patient to Dr Rotblatt as Dr Whitmore had confirmed that the patient remained HTLV-3 positive following receipt of heat-treated Factorate.
A memo from Dr Harris to Mr Christie outlined that on 27 February 1986 Dr Harris visited Dr Whitmore at Lewisham Hospital and followed up the history of two people with haemophilia who had seroconverted to HTLV-3 positive following treatment with heat-treated Factorate. Read more about A memo from Dr Harris to Mr Christie outlined that on 27 February 1986 Dr Harris visited Dr Whitmore at Lewisham Hospital and followed up the history of two people with haemophilia who had seroconverted to HTLV-3 positive following treatment with heat-treated Factorate.
The minutes of the Plasma Executive Committee noted that centres where unscreened donor product may have been delivered would not be contacted until the situation was clear. Read more about The minutes of the Plasma Executive Committee noted that centres where unscreened donor product may have been delivered would not be contacted until the situation was clear.
An internal correspondence from Dr William Terry noted that due to contractual arrangements Dr Prince was precluded from publishing, without their approval, data from experiments supported by RHCG. Read more about An internal correspondence from Dr William Terry noted that due to contractual arrangements Dr Prince was precluded from publishing, without their approval, data from experiments supported by RHCG.
"The Advocate" newspaper article noted that in the early 1980s drug companies turned down a chemical process that could have prevented the infection of thousands of people with haemophilia with AIDS. Read more about "The Advocate" newspaper article noted that in the early 1980s drug companies turned down a chemical process that could have prevented the infection of thousands of people with haemophilia with AIDS.
A letter from Dr Sternberg noted that by 1980 the research and development department of Cutter had made a strategic commitment that all new plasma products would be pasteurised. Read more about A letter from Dr Sternberg noted that by 1980 the research and development department of Cutter had made a strategic commitment that all new plasma products would be pasteurised.
Hyland listed hepatitis risk removal from Hemofil as a project proposal. It noted that the removal of the risk of hepatitis transmission by Hemofil was needed in order to allow sales of the project excess inventories at the highest possible selling price. Read more about Hyland listed hepatitis risk removal from Hemofil as a project proposal. It noted that the removal of the risk of hepatitis transmission by Hemofil was needed in order to allow sales of the project excess inventories at the highest possible selling price.
Hyland had heard that the clinical trials of the Behringwerke product were almost complete and had promising results. Read more about Hyland had heard that the clinical trials of the Behringwerke product were almost complete and had promising results.